NONOF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 19, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 62 instances where the indicator turned negative. In of the 62 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NONOF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NONOF's RSI Indicator exited the oversold zone, of 5 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NONOF advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .
NONOF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 283 cases where NONOF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.964) is normal, around the industry mean (14.746). P/E Ratio (26.852) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (1.283) is also within normal values, averaging (1.853). Dividend Yield (0.018) settles around the average of (0.013) among similar stocks. P/S Ratio (9.398) is also within normal values, averaging (264.084).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NONOF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
NWAWX | 15.43 | 0.12 | +0.78% |
Nationwide GQG US Quality Eq Instl Ser | |||
FIQKX | 10.29 | 0.06 | +0.59% |
Fidelity Advisor International Value Z | |||
GHAIX | 40.56 | 0.20 | +0.50% |
VanEck Global Resources Fund I | |||
LMGNX | 65.92 | 0.16 | +0.24% |
ClearBridge International Growth I | |||
FSQIX | 9.42 | N/A | N/A |
Fidelity Advisor Sustainable Intl Eq I |
A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.
Ticker / NAME | Correlation To NONOF | 1D Price Change % | ||
---|---|---|---|---|
NONOF | 100% | -4.67% | ||
NVO - NONOF | 70% Closely correlated | -5.27% | ||
LABFF - NONOF | 23% Poorly correlated | N/A | ||
IMRN - NONOF | 22% Poorly correlated | +8.59% | ||
QSI - NONOF | 21% Poorly correlated | -11.81% | ||
VRTX - NONOF | 21% Poorly correlated | +1.21% | ||
More |
Ticker / NAME | Correlation To NONOF | 1D Price Change % |
---|---|---|
NONOF | 100% | -4.67% |
Pharmaceuticals category (309 stocks) | 36% Loosely correlated | +0.20% |